Therapeutic Potential of Nerve Growth Factor Signaling Blockers against Castration-Resistant Prostate Cancers
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 373
Special Issue Editor
Interests: drug/drug interaction; metabolic syndrome; natural compounds
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Castration resistance prostate cancer (CRPC), including androgen-independent and neuroendocrine phenotypes, is frequently observed in recurrent patients with prostate cancer after treatment with androgen deprivation therapy. Due to the loss of growth signaling from the androgen receptor, various alternative growth signals are turned on in CRPC cells, particularly nerve growth factor (NGF) signaling. Recent studies have demonstrated that activated NGF signaling mediates treatment-mediated neuroendocrine transformation, an advanced CRPC sub-phenotype with high mortality and low responding rate to conventional treatment. Furthermore, gastroenteropancreatic neuroendocrine patients benefit from receiving NGF signaling blockers and immune checkpoint inhibitors. Additionally, the NGF receptor inhibitor reduces the tumor growth of androgen-independent prostate cancer cell lines in vitro. These studies imply that modulating the activity of NGF signaling may benefit the tumor control of CRPC and neuroendocrine tumors, which is not evaluated yet. This Special Issue aims to collect studies on the therapeutic potential of NGF blockers on CRPC, such as the discovery of new NGF blockers or combinations, clinical trials of NGF signaling blockers against CRPCs, and reviews for stratifying CRPC patients with clinical benefit from NGF signaling blockers.
Dr. Shian-Ren Lin
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nerve growth factor
- castration resistance
- neuroendocrine
- androgen deprivation
- androgen independence
